Zinc for Kids
A Real Role in Diarrhea, Oversold for Colds
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The grade is anchored to the specific claim that has guideline consensus: oral zinc alongside oral rehydration for acute and persistent childhood diarrhoea in children six months and older, especially where zinc deficiency or malnutrition is common. WHO and UNICEF have jointly recommended zinc (10 to 20 mg/day for 10 to 14 days) with low-osmolarity ORS since their 2004 joint statement, and WHO's ELENA guidance maintains it. This rests on a large multi-RCT base: the 2016 Cochrane review (Lazzerini and Wanzira, 33 trials, 10,841 children) and a 2024 WHO-commissioned meta-analysis (Das and colleagues, Aga Khan University, 38 trials, 33,693 children) both find zinc shortens diarrhoea and improves recovery, warranting grade 4 for that use. The Cochrane review is explicit that benefit is clearest in children older than six months and in deficiency or malnutrition settings, and does not support zinc in infants under six months or in well-nourished, low-deficiency-risk children. The separate cold-prevention claim is weak: the 2024 Cochrane common-cold review (Nault and colleagues), drawn mostly from adults, found only low-certainty signals, no clear preventive effect, and more non-serious side effects, so that use alone would grade near grade 2. The composite entry earns grade 4 on the strength of the diarrhoea guideline consensus, with the cold caveat kept explicit rather than folded into the grade.
- FDA
- Regulated as a supplement; WHO recommends zinc for childhood diarrhea
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Zinc is generally well tolerated at recommended amounts; the most common side effect in the diarrhea trials is vomiting, which is less frequent at lower doses, one reason recent reviews suggest reducing the diarrhea dose. Tolerable upper intake limits are low in young children (for example 7 mg/day for ages 1-3 and 12 mg/day for ages 4-8, per NIH), and chronic excess can interfere with copper absorption, so zinc should be matched to age and not stacked across multiple products. Separately, zinc-containing intranasal cold gels are a different product entirely and have been associated with loss of smell; this dossier concerns oral zinc, not nasal products. As with all supplements, products should be stored safely out of reach. Any decision about giving a child zinc, especially for an illness such as diarrhea, should be made with a pediatrician or qualified clinician rather than from marketing copy; this entry is educational and is not dosing guidance.
Zinc is an essential trace mineral that acts as a catalyst in hundreds of enzyme reactions and supports immune function and normal growth, and it has one genuinely strong pediatric use: treating childhood diarrhea. A 2016 Cochrane review of 33 trials in 10,841 children found zinc shortens diarrhea and reduces the chance it persists to day 7, with the clearest, high-certainty benefit in children showing signs of malnutrition, and a 2024 WHO-commissioned meta-analysis of 38 trials in over 33,000 children reached the same conclusion. This is why WHO and UNICEF recommend zinc alongside oral rehydration for young children with diarrhea, an intervention associated with lower mortality in low-income settings where diarrhea remains a leading cause of child death. The cold story is much weaker: the 2024 Cochrane common-cold review, drawn mostly from adults, found only low-certainty signals and little clear preventive effect, and separate 2024 work found no benefit in well-nourished children, despite zinc's prominence in immune gummies.
A genuine, globally important treatment for childhood diarrhea, especially in lower-income countries, and a much weaker story for preventing colds in healthy kids.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
What people get wrong
Often saidZinc gummies keep my healthy kid from catching colds.
ActuallyThe 2024 Cochrane review on zinc for the common cold, drawn mostly from adult participants, found little or no reduction in the risk of catching a cold and only low-certainty evidence of any effect on duration, with more non-serious side effects such as nausea and bad taste. A separate 2024 systematic review found no benefit in well-nourished children in high-income settings. Zinc's strong, well-supported pediatric use is treating diarrhea, especially where zinc deficiency is common, not cold prevention in well-nourished kids.
Often saidZinc is only useful as an immune booster.
ActuallyZinc's best-evidenced pediatric role is treating childhood diarrhea, a WHO- and UNICEF-recommended intervention associated with lower child mortality in low-income countries. The 2016 Cochrane review and a 2024 WHO-commissioned meta-analysis of 38 trials both support it. That is a very different, and much stronger, use than the immune-gummy framing suggests.
Often saidMore zinc works better, so a bigger dose helps.
ActuallyThe 2020 NEJM trial in 4,500 children found lower doses of 5 to 10 mg were as effective as the standard 20 mg for diarrhea and caused significantly less vomiting, and the 2024 WHO-commissioned review concluded the recommended dose should be reduced. Above age-specific tolerable upper limits (for example 7 mg/day for ages 1-3 and 12 mg/day for ages 4-8 per NIH), chronic excess can interfere with copper absorption. More is not better.
Who profits, and who pushes back
WHO & UNICEF
Children under five with diarrhea should receive 10 to 20 mg of oral zinc daily for 14 days; zinc shortens diarrhea and reduces its persistence, a key intervention in low-income settings.
Cochrane Review (33 trials, 10,841 children)
Zinc shortens diarrhea duration by about half a day in children over 6 months and reduces persistence by about 27%, with the clearest benefit in malnourished children, though the optimal dose may be lower.
Pediatric cold-evidence reviewers
Evidence that zinc prevents or shortens colds in healthy children is limited and inconclusive, in contrast to the stronger diarrhea data.
Immune-gummy marketing
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Promotes zinc (often with vitamin C and elderberry) as immune protection for all children, leaning on the strong diarrhea data and adult cold studies to imply a benefit not established for healthy kids' colds.
Where the research comes from
Most of the published research on this comes from one place. 70% of it is from Diarrhea benefit (LMIC). Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| Diarrhea benefit (LMIC) | 70% |
| Cold benefit (healthy kids) | 30% |
Research published from: Global.
How we got here
Zinc's role in childhood diarrhoea was established largely through randomized trials conducted in South and Southeast Asian and other lower-income settings with high zinc-deficiency rates. The Zinc Investigators' Collaborative Group pooled analyses (1999 to 2000), led by researchers including Zulfiqar Bhutta of Aga Khan University in Karachi, drew together trials from Bangladesh, India, Nepal, Pakistan, Peru and elsewhere showing zinc reduced diarrhoea and pneumonia in children in developing countries. That evidence led WHO and UNICEF to issue a joint statement in May 2004 recommending zinc plus low-osmolarity oral rehydration salts as a cornerstone of diarrhoea management, a recommendation later refined by the 2020 NEJM lower-dose trial and the 2024 WHO-commissioned meta-analysis toward a reduced dose. This deficiency-context, equity-focused base is distinct from, and much stronger than, the later marketing of zinc for cold prevention in well-nourished children.
Zinc's role in childhood diarrhea was established through trials led largely from and conducted in South and Southeast Asian and other lower-income settings with high zinc-deficiency rates. The Zinc Investigators' Collaborative Group, whose pooled analyses (1999-2000) were led by researchers including Zulfiqar Bhutta of Aga Khan University in Karachi, Pakistan, drew together randomized trials from Bangladesh, India, Pakistan, Peru and elsewhere showing zinc reduced diarrhea and pneumonia in children in developing countries. Large community-randomized effectiveness work followed in Bangladesh, India and Mali. This evidence led WHO and UNICEF to issue a joint statement in May 2004 recommending zinc plus low-osmolarity oral rehydration salts as a cornerstone of diarrhea management. That equity-focused, deficiency-context evidence base is distinct from, and much stronger than, the later marketing of zinc for cold prevention in well-nourished children, where the data have not matched the claims.
- 1999-2000Zinc Investigators' Collaborative Group (Bhutta, Black, Brown and others) publish pooled analyses of trials across developing countries showing zinc reduces childhood diarrhea and pneumonia
- 2004WHO and UNICEF issue a joint statement recommending zinc for 10-14 days plus low-osmolarity ORS for childhood diarrhea
- 2000sCommunity effectiveness programs scale zinc plus ORS in Bangladesh, India and Mali
- 2016Cochrane review (Lazzerini and Wanzira, 33 trials, 10,841 children) confirms diarrhea benefit, strongest in malnourished children
- 2020NEJM multicenter trial in India and Tanzania (4,500 children) finds lower zinc doses non-inferior with less vomiting
- 2024Cochrane common-cold review (mostly adults) reports only low-certainty benefit; WHO-commissioned meta-analysis (38 RCTs) reaffirms diarrhea use and supports a reduced dose
At a glance
- WHO diarrhea dose
- 10-20 mg/day for 14 days
- Ages 1-3 RDA
- 3 mg/day
- Diarrhea (LMIC)
- Shortens duration, cuts persistence
- Colds (healthy kids)
- Little clear evidence
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Zinc for Kids. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
WHO and UNICEF jointly recommend zinc (10 to 20 mg/day for 10 to 14 days) alongside low-osmolarity oral rehydration salts for children under five with diarrhoea, an intervention associated with reduced child deaths.
WHO/UNICEF Joint Statement, Clinical Management of Acute Diarrhoea (2004)
WHO recommends zinc supplementation as part of diarrhoea treatment in children, reflecting evidence that it reduces duration and severity of diarrhoeal episodes.
WHO ELENA, Zinc supplementation in the management of diarrhoea
In children older than six months, zinc may shorten acute diarrhoea by roughly half a day and probably shortens persistent diarrhoea; benefit is clearest in deficiency or malnutrition settings, and evidence does not support zinc in infants under six months or in well-nourished, low-risk children.
A WHO-commissioned systematic review of 38 trials in 33,693 children found zinc improved recovery and reduced diarrhoea duration in acute and persistent watery diarrhoea, with more vomiting in the zinc group and fewer vomiting episodes at lower doses.
In 4,500 children aged 6 to 59 months in India and Tanzania, 5 mg and 10 mg daily zinc were noninferior to the standard 20 mg for acute diarrhoea and caused less vomiting.
For the common cold, evidence is insufficient to recommend zinc: no clear preventive effect, only low-certainty evidence that treatment may shorten duration, and probably more non-serious adverse events such as nausea and unpleasant taste.
Tolerable upper intake levels for zinc are 7 mg/day for ages 1 to 3 and 12 mg/day for ages 4 to 8; excess zinc interferes with copper absorption and can cause copper deficiency, and high doses cause nausea and gastric distress.
NIH Office of Dietary Supplements, Zinc Fact Sheet for Health Professionals
UNICEF supplies ORS and zinc as co-packaged commodities for childhood diarrhoea, reflecting the joint recommendation and its role in reducing under-five mortality in lower-income settings.
UNICEF Supply Division, Oral rehydration salts (ORS) and zinc
Full text of the 2016 Cochrane review confirms the trial count (33), participant count (10,841), certainty grading and the qualification of benefit to children over six months in deficiency settings.
Lazzerini M, Wanzira H. Oral zinc for treating diarrhoea in children (full text via PMC)